Apremilast did not to reduce time to recovery or mortality in critically ill patients in phase II I-SPY COVID Trial

Study found that addition of apremilast (30 mg twice daily for up to 14 days) to backbone therapy, consisting of dexamethasone and remdesivir, did not impact recovery, defined as reduction in oxygen demand, or reduce mortality vs backbone therapy alone.

Source:

Biospace Inc.